康方生物:AK112联合化疗一线治疗SQ-NSCLC(VS替雷利珠单抗联用化疗)MPFS取得强阳性结果

中金公司
Yesterday

公司近况4 月23 日,公司宣布AK112 联合化疗对比替雷利珠单抗联合化疗用于治疗1L sqNSCLC的注册性III期临床(AK112-306/HARMONi-6)期中分析达到主要终点。评论AK112+化疗III期临床期中分析撞线,进度超我们预期。据公司公告,本项临床主要终点是PFS,基于IDMC期中分析,达到主要研究终点,获得了决定性胜出的阳性结果。本临床试验中央型鳞癌占比约为63%,与...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10